What is Helix?
Helix operates as a premier population genomics enterprise, functioning at the critical intersection of clinical care, research, and advanced genetic analysis. By leveraging one of the world's largest CLIA/CAP next-generation sequencing laboratories and its proprietary Exome+ assay, the firm provides an end-to-end platform for health systems, payers, and life sciences organizations. The company's market position is defined by its capacity to facilitate large-scale recruitment, engagement, and the seamless integration of genomic data into routine medical practice, thereby accelerating the transition toward precision medicine.
How much funding has Helix raised?
Helix has raised a total of $383M across 4 funding rounds:
Series A
$100M
Series B
$200M
Grant
$33M
Series C
$50M
Series A (2015): $100M with participation from Illumina, Warburg Pincus, and Sutter Hill Ventures
Series B (2018): $200M led by Sutter Hill Ventures, Warburg Pincus, Kleiner Perkins Caufield & Byers, Draper Fisher Jurvetson (DFJ), Mayo Clinic, and Illumina
Grant (2020): $33M supported by U.S. National Institutes of Health (NIH)
Series C (2021): $50M featuring Mayo Clinic, Temasek, Warburg Pincus, DFJ Growth, and Kleiner Perkins
Key Investors in Helix
Illumina
Illumina is a global leader in sequencing and array-based solutions, providing the core instrumentation and consumables necessary for high-throughput genomic analysis.
Warburg Pincus
Warburg Pincus is a prominent global private equity firm with a deep focus on growth-stage investments and long-term value creation across diverse industrial sectors.
Sutter Hill Ventures
Sutter Hill Ventures is a Palo Alto-based firm specializing in financing technology-driven startups and providing strategic operational support to scale market-leading enterprises.
What's next for Helix?
With the support of its latest financing, Helix is well-positioned to expand its footprint in the clinical genomics market. The company is expected to prioritize the enhancement of its translational research capabilities and the broader deployment of its disease screening tools. By deepening its partnerships with major healthcare institutions and life sciences entities, Helix aims to solidify its role as the foundational infrastructure for population-level health initiatives, driving long-term value through the democratization of genomic insights in clinical settings.
See full Helix company page
